Na Yin1, Chenting Wu1, Jianping Qiu2, Yueming Zhang3, Le Bo1, Ying Xu2, Mengdie Shi2, Songyue Zhu1, Guangzhao Yang1, Caiping Mao4. 1. Reproductive Medicine Center, The First Affiliated Hospital of Soochow University, 188 Shizi Rd, Suzhou, Jiangsu, China. 2. Department of Gynaecology, The Affiliated Suzhou Municipal Hospital of Nanjing Medical University, Suzhou, Jiangsu, China. 3. Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. 4. Reproductive Medicine Center, The First Affiliated Hospital of Soochow University, 188 Shizi Rd, Suzhou, Jiangsu, China. maocp1018@163.com.
Abstract
BACKGROUND: Umbilical cord-derived mesenchymal stem cell (UCMSCs) transplantation has been widely studied in premature ovarian failure (POF). However, the underlying mechanism remains elusive. This study aims to investigate the protective properties and mechanisms of heme oxygenase-1 (HO-1) expressed in UCMSCs in restoring the ovarian function of POF mice. METHODS: In in vitro and in vivo experiments, mice were treated with the presence or absence of the HO-1/shHO-1-transfected UCMSCs, and the administration of SP600125 or anisomycin, the inhibitor or activator of JNK. The viability and apoptosis of granulosa cells (GCs) at different time points of co-cultivation were assessed in vitro. In in vivo experiments, mouse ovarian function was assessed by detecting the serum levels of hormone and observing the ovarian morphological changes. Multiple molecular indices of JNK/Bcl-2 signal pathway were performed. And the autophagy changes in GCs were assessed by detecting the associated cytokines and observing the intracellular autophagosome accumulation. Additionally, the spleen levels of CD8+CD28- T cells and serum levels of interleukin 10 (IL-10) were tested to evaluate the immune mechanisms involved. RESULTS: UCMSCs transfected with shHO-1 or treated with SP600125 inhibited GCs' viability and promoted its apoptosis in a time-dependent manner in vitro. In in vivo experiments, mice in both groups showed little therapeutic efficiency which presented as the increased extent of ovarian fibrosis with decreased number of functional follicles, and disordered hormone production. Additionally, the JNK/Bcl-2-associated cytokines were obviously declined. The inhibited autophagy-related cytokines, the chromatin condensation and abound vacuolar autophagosome in GCs, and weakened fluorescence intensity by MDC were observed. The downregulated levels of CD8+CD28- T cells and serum levels of IL-10 were also detected. The damages above can be alleviated with HO-1-MSCs treatment or anisomycin administration. CONCLUSIONS: HO-1 expressed in UCMSCs is critical in restoring the ovarian function in POF mice with UCMSC transplantation, which is mediated by the activation of JNK/Bcl-2 signal pathway-regulated autophagy and upregulating the circulating of CD8+CD28- T cells.
BACKGROUND: Umbilical cord-derived mesenchymal stem cell (UCMSCs) transplantation has been widely studied in premature ovarian failure (POF). However, the underlying mechanism remains elusive. This study aims to investigate the protective properties and mechanisms of heme oxygenase-1 (HO-1) expressed in UCMSCs in restoring the ovarian function of POFmice. METHODS: In in vitro and in vivo experiments, mice were treated with the presence or absence of the HO-1/shHO-1-transfected UCMSCs, and the administration of SP600125 or anisomycin, the inhibitor or activator of JNK. The viability and apoptosis of granulosa cells (GCs) at different time points of co-cultivation were assessed in vitro. In in vivo experiments, mouse ovarian function was assessed by detecting the serum levels of hormone and observing the ovarian morphological changes. Multiple molecular indices of JNK/Bcl-2 signal pathway were performed. And the autophagy changes in GCs were assessed by detecting the associated cytokines and observing the intracellular autophagosome accumulation. Additionally, the spleen levels of CD8+CD28- T cells and serum levels of interleukin 10 (IL-10) were tested to evaluate the immune mechanisms involved. RESULTS: UCMSCs transfected with shHO-1 or treated with SP600125 inhibited GCs' viability and promoted its apoptosis in a time-dependent manner in vitro. In in vivo experiments, mice in both groups showed little therapeutic efficiency which presented as the increased extent of ovarian fibrosis with decreased number of functional follicles, and disordered hormone production. Additionally, the JNK/Bcl-2-associated cytokines were obviously declined. The inhibited autophagy-related cytokines, the chromatin condensation and abound vacuolar autophagosome in GCs, and weakened fluorescence intensity by MDC were observed. The downregulated levels of CD8+CD28- T cells and serum levels of IL-10 were also detected. The damages above can be alleviated with HO-1-MSCs treatment or anisomycin administration. CONCLUSIONS:HO-1 expressed in UCMSCs is critical in restoring the ovarian function in POFmice with UCMSC transplantation, which is mediated by the activation of JNK/Bcl-2 signal pathway-regulated autophagy and upregulating the circulating of CD8+CD28- T cells.
Entities:
Keywords:
Autophagy; CD8+CD28− T cells; Heme oxygenase-1; JNK/Bcl-2 signal pathway; Premature ovarian failure; Umbilical cord-derived mesenchymal stem cells
As a heterogeneous disorder, premature ovarian failure (POF) is prevalent in 1–3% of women under 40 years old, and its features include the disordered ovarian function, the elevated gonadotropin hormone, and descended estrogen levels [1]. However, the more efficient therapeutic methods remain to be explored. With the ability of directionally differentiating into specific cells under specific microenvironments, secreting paracrine cytokines, regulating inflammation, and enhancing endogenous tissue repair [2], increasing evidences have proposed the transplantation of mesenchymal stem cells (MSCs) to be a potential therapy of treating POF disorder [3, 4]. Additionally, with the characteristics of easy extraction and low immunogenicity, human umbilical cord-derived mesenchymal stem cells (UCMSCs) have been recognized as the preferred MSCs for transplantation [5].Heme oxygenase-1 (HO-1) expressed in most cells, which has potent anti-inflammatory, antioxidant, and immunoregulatory properties [6]. Researches have illustrated that MSCs can upregulate the expression of HO-1, which plays a critical therapeutic role [7]. It also participates in the physiology of the ovary [8] and the secretion of gonadotropins from the pituitary gland [9]. It has been proved that in various disease conditions, HO-1 induction is an adaptive defense mechanism to maintain the function of cells and tissues [10, 11]. However, much less is comprehended of the role and mechanism of HO-1 in recovering the ovarian function of POFmice with UCMSC transplantation. Attentions have been drawn to the HO-1-mediated autophagy pathway [12, 13]. In physical conditions, autophagy maintains cellular homeostasis [14-16], while under short-term stress, it promotes survival and viability [17]. In the ovary, autophagy in murine newborns participates in preserving the primordial oocyte pool [18] and is relevant to oocyte elimination during follicular atresia [19]. Researches showed that autophagy can be activated and weakened the restrain of Bcl-2 on Beclin-1 through activating the JNK/Bcl-2 signal pathway [20]. Moreover, autophagy is recognized to have participated into both innate and adaptive immunity [21].CD8+ regulatory T (Treg) cells are known essential in various inflammatory disorders and autoimmune diseases [22]. As an important subset of CD8+Tregs, CD8+CD28− T cells display typical immunosuppressive function [23]. Furthermore, evidences suggest that CD8+CD28− T cells can induce immunological tolerance in transplantation, demonstrating immunologic suppression in organ transplants [24]. The expanding of the cells may be the mechanism of primary tolerance in bone morrow transplantation, improving the acceptability of graft and stabilizing its function, and its enhanced expansion is the reason of reduced immune rejection [25, 26]. To date, the altered expression of CD8+CD28− T cells have been observed in many disease, including autoimmunity and chronic inflammatory disease [25, 27]. However, whether and how the UCMSC transplantation effect the expression of the CD8+CD28− T cells should still be explored.In this report, the HO-1/shHO-1 gene was incorporated into UCMSCs through plasmid transduction, aiming to explore the role and mechanism of HO-1 gene in recovering ovarian function of POFmice with UCMSC transplantation. And the research will supply helpful information in treating POFpatients with MSCs transplantation in the clinic.
Materials and methods
Animals
Six-week-old female mice (for researches in vivo) and 3-week-old female mice (for researches in vitro) (C57BL/6) were purchased from Suzhou Zhaoyan Biotechnology Co. (Jiangsu, China). All the animals were housed and fed with proper diet.
Isolation, culture, and identification of human UCMSCs and mouse ovarian granular cells (GCs)
Human umbilical cords were acquired from parturient woman with negative infectious diseases, and the written and informed consent was obtained for the umbilical cord sample will be used for research purpose. The umbilical cords were washed and cut into small pieces (1 mm3) without the blood vessels and placed onto plates with culture medium and maintained at 37 °C. The media were renewed at intervals of 2–3 days. To identify the UCMSCs, cell morphology was observed under inverted fluorescence microscope (Nikon, Japan). For osteogenic and adipogenic differentiation, alizarin red staining and Oil Red O staining (Cyagen, USA) were used separately to identify osteoblast-like cells and adipose cells. Additionally, the molecular markers of UCMSCs such as CD14, CD29, CD34, CD90, CD31, and HLA-DR were examined using FCM [28]. Cells used in the experiments were after three passages.The pregnant mare serum gonadotropin (Solarbio, CN) were injected into 3-week-old female mice (i.p.), and mouseovaries were extracted with peripheral adhesion tissues removed under sterile conditions 48 h later. To obtain single-cell suspension, the ovaries were washed and the GCs were released from follicles under an anatomical microscope. After washing with PBS, the cells were cultured at 37 °C, 5% CO2. First passage of GCs was used in the experiments. To identify the GCs, the expression of follicle-stimulating hormone receptor (FSHR) was detected by immunohistochemistry. After fixation and penetration, GCs were incubated overnight at 4 °C with rabbit anti-mouseFSHR antibody (1:150, proteintech, CN). And the secondary biotinylated goat anti-rabbit lgG antibody (1:300, Beyotime, CN) were used, following with DAB dye liquor. The dyeing conditions were recorded with inverted fluorescence microscope [4].
Modification of HO-1 gene in UCMSCs via plasmid transfection
Before the transfection of HO-1/shHO-1(used to knock down HO-1 levels)/NC (empty vector) gene described by the manufacturer (Ribobio, CN), 2 × 105 cells/well of UCMSCs were added into the 24-well transwell plates for 24 h. A non-targeting RNA was used as control, and two targeting RNAs were used in the transfection. Briefly, UCMSCs were incubated with plasmid for 24 h at 37 °C. And the culture medium was changed to incubate another 2 days. After RNAs and of Lipofectamine 3000 (Invitrogen, USA) were separately mixed with serum-free DMEM, the diluents were mixed and incubated at room temperature (RT) for 20 min, then were added into the cells and cultured for 72 h at 37 °C, 5% CO2. The transfection efficiency of HO-1 was investigated by the quantitative reverse-transcription polymerase chain reaction (qRT-PCR).
UCMSC and GC transwell co-culture
The co-culture of UCMSCs and GCs was conducted based on the methods reported [29]. Briefly, 1 × 105 cells/well of UCMSCs were seeded onto 24-well transwell permeable support (pore size, 0.4 μm, Corning, NY, USA), and cultured overnight at 37 °C, 5% CO2. Then, 5 × 104 cells/well of GCs were seeded into the bottom of 24-well plates. After co-cultivation for 24 h, the following experiments were operated.
Measurement of GCs’ viability by Cell Counting Kit-8 (CCK-8) analysis
In in vitro experiments, 5 mg/L chlormethine hydrochloride (HN2) were used to simulate POF model. The GCs’ viability was assessed according to the manufacturer’s instructions (MCE, USA). Briefly, 5 × 103 cells/well of GCs were seeded in triplicate in 96-well plates and were co-cultured with the supernatant of UCMSCs transfected with the plasmids of HO-1/shHO-1/NC for 24 h prior to exposure to SP600125 (0–20 μM) or anisomycin (0–20 μM) for 12 h, 24 h, 48 h, and 72 h, respectively. Then, the medium was removed with fresh medium containing 10 μl of CCK-8 reagent added and incubated at 37 °C for 2 h. Absorbance (λ/nm = 450) was measured using a SpectraMax M2e microplate reader (Molecular Devices, USA). The GCs’ viability shows as the ratios of the OD values in the treated groups to the control group.
Apoptosis assay by FCM
The FITCAnnexin V apoptosis detection kit (Beyotime, CN) was used to assess the GC apoptosis. After collecting, washing the GCs, 500 μl 1× binding buffer mixed with 5 μl of Annexin-V-fluorescein isothiocyanate (FITC) and 10 μl of propidium iodide (PI) were added and detected using FCM (BD, USA).
MDC staining
According to manufacturer’s protocols, 5 × 103 cell/well of GCs were incubated in 96-well plates and treated with HN2 for 12 h and then were co-cultured with the supernatant of UCMSCs transfected with the plasmids of HO-1/shHO-1/NC for 24 h prior to exposure to SP600125 or anisomycin, respectively. After 48-h treatment, 100 μM of MDC was added for 15–60 min. After washing with 100 μl wash buffer, optical density was calculated by the inverted fluorescence microscope and analyzed by Image J software.
Animal model establishment
Six-week-old mice (n = 81) were randomly divided into nine groups (n = 9): control group (A), POF group (B), POF+ UCMSCs group (C), POF+ NC-UCMSCs group (D), POF+ HO-1-UCMSCs group (E), POF+ shHO-1-UCMSCs group (F), POF+ UCMSCs+ DMSO group (G), POF+ UCMSCs+ SP600125 group (H), and POF+ UCMSCs+ Anisomycin group (I). Mice in group A received no treatments. Mice in groups B–I were injected i.p. with cyclophosphamide (120 mg/kg) and busulfan (30 mg/kg) [30]. 1 × 106 MSCs of 6th passages were suspended with PBS and injected into mice in groups C, G, H, and I, and MSCs transfected with NC, HO-1, or shHO-1 gene were separately injected into mice in groups D, E, and F 2 weeks later, according to the previous studies [31-33]. Another 5 days later, mice in groups H and I were treated with SP600125 (MCE, USA, 15 mg/kg, i.p.) or anisomycin (Selleck, USA, 5 mg/kg, i.p.), respectively. In mice of group G, 0.01% DMSO were treated (i.p.) as a vehicle control of groups H and I. Then 48 h later, all mice were sacrificed to do the following experiments.
Serum levels of hormone and interleukin (IL-10) measurement
Blood samples of mice were taken from postcava and centrifuged to get the serum. The ELISA kits (Greenleaf, CN) were used to survey the levels of estradiol (E2), follicle stimulation hormone (FSH), luteinizing hormone (LH), anti-Müllerian hormone (AMH), and IL-10 according to the instructions of manufacturers.
Follicle counting and ovarian morphological analysis
Before staining with HE for histopathology, mouseovaries were kept and fixed. The ovarian histological changes were observed by light microscopy (Olympus). We counted the follicles containing obvious nucleus in the experiment, which were divided into primordial, primary, secondary, antral, and atretic follicles, which were described before [3, 34].
QRT-PCR
The RNeasy Mini Kits (Qiagen, Germany) were used to extract RNA from mouseovaries based on the manufacturer’s protocols. To generate cDNA, 1 μg of RNA with oligo dT and a reverse transcription kit (Transgen Biotech, CN) was used. The primers are presented in Table 1, and FastStart Universal SYBR Green Master (Thermo Fisher Scientific, USA) were used to carry quantitative PCR with the StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, USA). GAPDH was used for control. Each sample was tested three times [3].
Table 1
Sequences of the primers used in QRT-PCR
Target gene
Primer
Nucleotide sequence
h-GAPDH
F
5′-GGAGCGAGATCCCTCCAAAAT-3′
R
5′-GGCTGTTGTCATACTTCTCATGG-3′
h-HO-1
F
5′-AAGACTGCGTTCCTGCTCAAC-3′
R
5′-AAAGCCCTACAGCAACTGTCG-3′
m-GAPDH
F
5′-AGGTCGGTGAACGGATTTG-3′
R
5′-TGTAGACCATGTAGTTGAGGTCA-3′
m-BCL-2
F
5′-GCTACCGTCGTGACTTCGC-3′
R
5′-CCCCACCGAACTCAAAGAAGG-3′
m-Beclin1
F
5′-ATGGAGGGGTCTAAGGCGTC-3′
R
5′-TCCTCTCCTGAGTTAGCCTCT-3′
m-p62
F
5′-AGGATGGGGACTTGGTTGC-3′
R
5′-TCACAGATCACATTGGGGTGC-3′
m-LC3I/II
F
5′-GACCGCTGTAAGGAGGTGC-3′
R
5′-CTTGACCAACTCGCTCATGTTA-3′
m-Atg5
F
5′-TGTGCTTCGAGATGTGTGGTT-3′
R
5′-GTCAAATAGCTGACTCTTGGCAA-3′
m-HO-1
F
5′-AAGCCGAGAATGCTGAGTTCA-3′
R
5′-GCCGTGTAGATATGGTACAAGGA-3′
Sequences of the primers used in QRT-PCR
Western blotting
Ovaries were lysed by radioimmunoprecipitation assay (RIPA) buffer. After measuring the concentration of the protein, 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) gel electrophoresis was used to separate and transferred to the membrane, which was blocked with serum blocking solution, and then incubated overnight at 4 °C with primary antibodies against JNK, p-JNK, and HO-1 (1:1000, Proteintech, USA); Bcl-2, Beclin-1, Atg5, p62, and LC3I/II (1:1000, CST, USA); and GAPDH (1:50000, Proteintech). After three times of washing, the secondary antibodies were added to the membrane and incubated for 1 h at RT, then detected using the Super Enhancer chemiluminescence (ECL) Kit (Absin, CN). Results were analyzed by Image J software.
Transmission electron microscopy (TEM)
The ovaries were rinsed twice with PBS and post-fixed in 1% osmium tetroxide (OsO 4) at 4 °C overnight; cells were dehydrated in graded alcohols, embedded in epoxy resins, sectioned and stained with uranyl acetate/lead citrate, and observed with TEM (FEI Tecnai Spirit, USA). Each group was prepared in three sections, and 200 cells were used to observe the autophagic structures.
Differentiation of CD8+CD28− T lymphocytes by FCM
Mice spleens were mechanically minced. After lysing with lymphocyte separation medium, cells were resuspended in PBS. With 10-min incubation of anti-mouseCD3 APC, anti-mouseCD8FITC, and anti-mouseCD28 PE (eBioscience, San Diego, USA) at 4 °C in the dark, the cell suspension was analyzed by FCM.
Data analysis
SPSS 16.0 software was applied to analyze the data for thrice in each experiment, which are then shown as the mean ± standard deviation. The Student t test was analyzed to compare each of the two groups. The distribution of data was analyzed by a one-way analysis of variance (ANOVA). P value of < 0.05 refers statistically significant.
Results
The primary culture of UCMSCs and GCs, and the transduction efficiency of UCMSCs with HO-1/shHO-1/NC plasmids
Individual clone spheres were formed until 7–10 days after inoculation and displayed fibroblast-like morphology (Fig. 1b). Stable cell population can be observed three passages later, and no visible morphologic alteration was observed even following 10 passages. Positive expression of CD29, CD44, and CD90 were detected with the immunophenotyping analysis. And the negative expression of CD34, CD14, and HLA-DR were detected (Fig. 1a). In osteoblastic induction medium, von Kossa staining showed calcium deposition (Fig. 1c). In adipogenic induction medium, and Oil Red O staining to observe the lipid droplets in the cytoplasm was positive (Fig. 1d), which were consistent with the researches published [35]. A significantly higher expression levels of HO-1mRNA were observed in the HO-1 plasmid transduction group (P < 0.001), and lower expression was in the shHO-1 plasmid transduction group comparing with the NC transduction group (P < 0.05) (Fig. 1g), which represents that the HO-1/shHO-1 plasmids have been effectively transfected into UCMSCs.
Fig. 1
Identification of UCMSCs and GCs, and the transduction efficiency of the HO-1/shHO-1 plasmids into UCMSCs. a Black histograms represent expression of indicated cell surface marker. b Cultured UCMSCs show fibroblast-like morphology (× 100). c, d UCMSCs cultured under conditions for differentiation into osteoblasts or lipoblasts. Osteoblasts are displayed by Alizarin Red staining and darker red staining indicates calcium deposition (× 200, c). Lipoblasts displayed by accumulation of neutral lipid vacuoles stained with Oil Red O (× 400, d). e, f Morphology and phenotypes of GCs. Cultured GCs show spindle-shaped morphology (× 100, e). Blue staining indicates the GCs’ nucleus; brown staining indicates FSHR-positive expression in cytoplasm (× 400, f). g The transfection efficiency of the HO-1/shHO-1 plasmids into UCMSCs. *P < 0.05, ***P < 0.001 vs NC group. GCs, granulosa cells; HO-1, heme oxygenase-1; UCMSCs, umbilical cord mesenchymal stem cells
Identification of UCMSCs and GCs, and the transduction efficiency of the HO-1/shHO-1 plasmids into UCMSCs. a Black histograms represent expression of indicated cell surface marker. b Cultured UCMSCs show fibroblast-like morphology (× 100). c, d UCMSCs cultured under conditions for differentiation into osteoblasts or lipoblasts. Osteoblasts are displayed by Alizarin Red staining and darker red staining indicates calcium deposition (× 200, c). Lipoblasts displayed by accumulation of neutral lipid vacuoles stained with Oil Red O (× 400, d). e, f Morphology and phenotypes of GCs. Cultured GCs show spindle-shaped morphology (× 100, e). Blue staining indicates the GCs’ nucleus; brown staining indicates FSHR-positive expression in cytoplasm (× 400, f). g The transfection efficiency of the HO-1/shHO-1 plasmids into UCMSCs. *P < 0.05, ***P < 0.001 vs NC group. GCs, granulosa cells; HO-1, heme oxygenase-1; UCMSCs, umbilical cord mesenchymal stem cellsCells isolated from mouse ovarian follicles were observed as adherent growth after 24 h of inoculation and displayed polygon-like morphology (Fig. 1e). FSHR, which can serve as a marker of GCs, is positive in almost all of the cells’ cytoplasm (Fig. 1f), in accordance with our previous reports [3].
HO-1 expressed in UCMSCs increased GCs’ viability and decreased their apoptosis overtime
HO-1 expressed in UCMSCs induced GCs’ viability in a time-dependent manner (Fig. 2). All the viabilities in the treatment groups were significantly decreased compared with the GC group (P < 0.001) (Fig. 2a-1). To the time point of 24 h, the decreased viability in GCs treated with HN2 was significantly increased with the co-cultivation of MSCs or HO-1-MSCs, while with the co-cultivation of shHO-1-MSCs, the GCs’ viability showed lower than that in the NC group (P < 0.001) (Fig. 2a-2), which were similar to the tendency in 48 h (Fig. 2a-3). To the time point of 72 h, upregulated levels of the viability were detected in the HO-1 group than the NC group (P < 0.001), and the downregulated levels of viability was still presented in the shHO-1 group (P < 0.01) (Fig. 2a-4).
Fig. 2
The proliferation and apoptosis of GCs in different condition. The statistical charts of GCs viability co-cultured with UCMSCs transfected with the plasmids of HO-1/shHO-1 for 12 h (a-1), 24 h (a-2), 48 h (a-3), or 72 h (a-4). The tendency charts of GC proliferation administrated with anisomycin (0–20 μM) (a-5) or SP600125 (0–20 μM) for 12–72 h (a-6). The statistical charts of GCs’ apoptosis co-cultured with UCMSCs transfected with the plasmids of HO-1/shHO-1 for 12 h (b-1), 24 h (b-2), 48 h (b-3), or 72 h (b-4). The tendency charts of GC apoptosis administrated with anisomycin (0–20 μM) (b-5), or treated with SP600125 (0–20 μM) for 12–72 h (b-6). Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO group, GC group, or NC group, separately. DMSO, dimethylsulfoxide; GCs, granulosa cells; HO-1, heme oxygenase-1; NC, empty vector; UCMSCs, umbilical cord mesenchymal stem cells
The proliferation and apoptosis of GCs in different condition. The statistical charts of GCs viability co-cultured with UCMSCs transfected with the plasmids of HO-1/shHO-1 for 12 h (a-1), 24 h (a-2), 48 h (a-3), or 72 h (a-4). The tendency charts of GC proliferation administrated with anisomycin (0–20 μM) (a-5) or SP600125 (0–20 μM) for 12–72 h (a-6). The statistical charts of GCs’ apoptosis co-cultured with UCMSCs transfected with the plasmids of HO-1/shHO-1 for 12 h (b-1), 24 h (b-2), 48 h (b-3), or 72 h (b-4). The tendency charts of GC apoptosis administrated with anisomycin (0–20 μM) (b-5), or treated with SP600125 (0–20 μM) for 12–72 h (b-6). Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO group, GC group, or NC group, separately. DMSO, dimethylsulfoxide; GCs, granulosa cells; HO-1, heme oxygenase-1; NC, empty vector; UCMSCs, umbilical cord mesenchymal stem cellsAs expected, the GCs’ apoptosis was reduced over time with the co-cultivation of HO-1-UCMSCs (Fig. 2). Similar to the results presented in 12 h, no significant differences were detected among the treatment groups (P > 0.05), while it was obviously upregulated than that in 12 h (P < 0.001) (Fig. 2b-1). While to the time point of 24 h, the increased GCs’ apoptosis in the HN2 group can be reversed by treating with MSCs, and the apoptosis in the shHO-1 group was detected higher than the NC group (P < 0.01) (Fig. 2b-2). When it turns to 48 h, the apoptosis of GCs in the HO-1 group presented as significantly lower than that in the NC group (P < 0.01), while higher apoptosis still presented in the shHO-1 group (P < 0.01) (Fig. 2b-3), and similar tendencies can be observed when it turns to 72 h (Fig. 2b-4). From these tendencies, it can be preliminary indicated that HO-1 expressed in UCMSCs played an essential role in the therapeutic process of POFmice receiving UCMSC transplantation.
HO-1 expressed in UCMSCs help recover the ovarian function in POF mice
To further confirm the critical role of HO-1 expressed in the UCMSCs during the therapeutic process, the HO-1/shHO-1-MSCs were transplanted into POFmice and the ovarian function were analyzed. Results recognized that comparing with the control group, decreased levels of E2 (P < 0.01) and AMH (P < 0.001) and increased levels of FSH (P < 0.001) and LH (P < 0.001) were detected in the POF group, which can be reversed by the administration of MSCs (Fig. 3a-1, b-1, c-1). Similarly, the uptrend levels of E2 (P < 0.05), AMH (P < 0.05) and downtrend levels of FSH (P < 0.001) and LH (P < 0.01) can be observed in the HO-1 group, while decreased levels of E2 (P < 0.01), AMH (P < 0.001) and increased levels of FSH (P < 0.05) and LH (P < 0.01) were detected in the shHO-1 group compared with those in the NC group, which represents the obviously weakened therapeutic efficiency (Fig. 3a-3, b-3, c-3).
Fig. 3
Serum levels of E2, FSH, LH, AMH, and IL-10 in mice. a-1–a-3 E2 release. b-1–b-3 FSH release. c-1–c-3 LH release. d-1–d-3 AMH release. e-1–e-3 IL-10 release. Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; E2, estradiol; FSH, follicle stimulation hormone; HO-1, heme oxygenase-1; IL-10, interleukin-10; LH, luteinizing hormone; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
Serum levels of E2, FSH, LH, AMH, and IL-10 in mice. a-1–a-3 E2 release. b-1–b-3 FSH release. c-1–c-3 LH release. d-1–d-3 AMH release. e-1–e-3 IL-10 release. Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; E2, estradiol; FSH, follicle stimulation hormone; HO-1, heme oxygenase-1; IL-10, interleukin-10; LH, luteinizing hormone; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cellsLarge numbers of different stages of healthy follicles were contained in miceovaries of the control group, including primordial follicles (Fig. 4-1), primary follicles (Fig. 4-2), secondary follicles (Fig. 4-3), antral follicles (Fig. 4-4), and atretic follicles (Fig. 4-5). However, it presented as the atrophied ovaries in the POF group which showed serious fibrosis with a reduced number of function follicles (Fig. 4b), which showed the similar morphology to the shHO-1 group (Fig. 4f). With the MSC or HO-1-MSC administration, the morphology of ovaries gradually return to normal (Fig. 4c, e). Additionally, similar to the declined functional follicles (P < 0.05) and inclined atretic follicles (P < 0.01) in the POF group compared with the control group, a declined trend of primordial follicles (P < 0.05), secondary follicles (P < 0.05), and antral follicles (P < 0.05) were showed in the shHO-1 group comparing with the NC group (Fig. 4j, k). With the transfection of HO-1, the primary follicles were obviously upregulated (P < 0.05), along with downregulated number of the atretic follicles (P < 0.01). Based upon the results above, we can further confirm that HO-1 gene played a critical role during the therapeutic process of POFmice receiving MSC transplantation.
Fig. 4
Histopathological examination of ovarian tissues. Photomicrographs (× 100) show HE stained ovaries. a Control group. b POF group. c MSC group. d NC group. e HO-1 group. f shHO-1 group. g DMSO group. h Anisomycin group. i SP600125 group. The five types of ovarian follicles were marked as (1) primordial follicles, (2) primarily follicles, (3) secondary follicles, (4) antral follicles, and (5) atresia follicles. j–l Quantitation on follicle count from ovaries in mice of the nine groups. Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. Bar scale = 200 μm. DMSO, dimethylsulfoxide; HE, hematoxylin and eosin; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
Histopathological examination of ovarian tissues. Photomicrographs (× 100) show HE stained ovaries. a Control group. b POF group. c MSC group. d NC group. e HO-1 group. f shHO-1 group. g DMSO group. h Anisomycin group. i SP600125 group. The five types of ovarian follicles were marked as (1) primordial follicles, (2) primarily follicles, (3) secondary follicles, (4) antral follicles, and (5) atresia follicles. j–l Quantitation on follicle count from ovaries in mice of the nine groups. Data presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. Bar scale = 200 μm. DMSO, dimethylsulfoxide; HE, hematoxylin and eosin; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
HO-1 expressed in UCMSCs help recover the ovarian function of POF mice through activating the JNK/Bcl-2 signal pathway
To figure out whether and how the JNK/Bcl-2 signal pathway involved in the therapeutic process, in vivo and in vitro experiments were operated with or without the inhibitor or activator of the JNK/Bcl-2 signal pathway. In in vitro experiments, the GCs’ viability significantly declined with the administration of SP600125 in a time- and dose-dependent manner, observed at the concentrations below 15 μM to the time points of 48 h (Fig. 2a-6). Similarly, the GCs’ viability was promoted by the treatment of anisomycin at the concentration below 4 μM to the time points of 48 h (Fig. 2a-5). To further confirm the changes above, the apoptosis of GCs was analyzed. Decreased tendency of GCs’ apoptosis was observed with the treatment of anisomycin (Fig. 2b-5), while the usage of SP600125 can obviously increase the apoptosis as the dose and time increased (Fig. 2b-6). In in vivo experiments, the serum levels of E2 and AMH were inclined (P < 0.01 and P < 0.05) with the administration of anisomycin, but the levels of FSH (P < 0.001) and LH (P < 0.01) were declined compared with the DMSO group (Fig. 3). With the treatment of SP600125, the serum levels of E2 were and AMH were downregulated (P < 0.01 and P < 0.05) but the levels of FSH (P < 0.001) and LH (P < 0.05) were upregulated. In the aspect of morphology, shown in Fig. 4, the number of follicles in each stage showed the similar tendency with that in the anisomycin group. Meanwhile in the SP600125 group, mouseovaries displayed as reduced number of functional follicles (P < 0.05), along with increased number of atretic follicles (P < 0.05).To elucidate whether HO-1-MSCs played its role through activating the JNK/Bcl-2 signal pathway during the therapeutic process, the expression levels of HO-1 and the JNK/Bcl-2 signal pathway-related proteins and mRNA were detected. The HO-1 mRNA expression levels in the HO-1 group showed significantly upregulated compared with that in the NC group (P < 0.01), while it presented as downregulated in the shHO-1 group (P < 0.01). The expression levels of Bcl-2 mRNA were declined in the shHO-1 group (P < 0.01) but inclined in the HO-1 group (P < 0.001) compared with the NC group (Fig. 5b-2), and with the administration of SP600125, it showed significantly decreased compared with the DMSO group (P < 0.05, Fig. 5b-3). Corresponding to the tendencies above, the HO-1 protein levels were significantly increased in the HO-1 group when compared with the NC group (P < 0.01), while the tendency showed decreased in the shHO-1 group (P < 0.05, Fig. 6e). No significant changes were observed among the groups except the control group in JNK protein expression (P > 0.05, Fig. 6b). However, the p-JNK protein expressed in the HO-1 group were significantly increased (P < 0.01) but decreased obviously in the shHO-1 group (P < 0.01) compared with the NC group. With the administration of anisomycin, the expression levels of p-JNK were increased (P < 0.01), while the treatment of SP600125 can decrease the levels (P < 0.05, Fig. 6c). Increased levels were detected in the HO-1 group (P < 0.05), but no significant changes were observed in the shHO-1 group (P > 0.05), and the inclined tendency was presented in the anisomycin group (P < 0.05, Fig. 6d). Based on the results above, we can suggest that the ovarian function of POFmice receiving MSC transplantation may be restored through activating the JNK/Bcl-2 signal pathway.
HO-1, JNK/Bcl-2 signal pathway- and autophagy-related protein expression in ovarian tissues by western blot analysis. a The HO-1, JNK/Bcl-2 signal pathway- and autophagy-related protein expression in PVDF membrane. Quantification of b JNK, c p-JNK, d Bcl-2, e HO-1, f LC3II/I, g Beclin1, h p62, and i Atg5 protein expression. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
HO-1, Bcl-2, and autophagy-related mRNA expression in ovarian tissues by QRT-PCR. a-1–a-3 HO-1 mRNA expression. b-1–b-3 Bcl-2 mRNA expression. c-1–c-3 LC3II/I mRNA expression. d-1–d-3 p62 mRNA expression. e-1–e-3 beclin1 mRNA expression. f-1–f-3 Atg5 mRNA expression. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cellsHO-1, JNK/Bcl-2 signal pathway- and autophagy-related protein expression in ovarian tissues by western blot analysis. a The HO-1, JNK/Bcl-2 signal pathway- and autophagy-related protein expression in PVDF membrane. Quantification of b JNK, c p-JNK, d Bcl-2, e HO-1, f LC3II/I, g Beclin1, h p62, and i Atg5 protein expression. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
HO-1 expressed in UCMSCs induce robust autophagic flux through activating the JNK/Bcl-2 signal pathway in the therapeutic process
To further confirm whether and how the activating of JNK/Bcl-2 signal pathway regulates autophagy during the therapeutic process, the expression levels of the autophagy-related mRNA and proteins were detected, along with the accumulation of autophagosome detected by MDC analysis in vitro and TEM in vivo. Increased levels of LC3 I/II, Atg5, and Beclin1 mRNA (P < 0.001 and P < 0.01 and P < 0.001), along with decreased levels of p62 mRNA (P < 0.001), were observed in the HO-1 group, which showed similar tendencies with the anisomycin group. In mice with shHO-1-MSC transplantation, the GCs’ autophagy was inhibited which presented as decreased levels of LC3 I/II and Beclin1 mRNA (P < 0.001 and P < 0.01) and decreased levels of p62 mRNA (P < 0.01), showing the similar tendency as the SP600125 administration (Fig. 5). For the aspect of the protein expression, HO-1-MSC administration can induce the autophagy in GCs showed as increased protein levels of LC3 I/II (P < 0.001), while shHO-1-MSCs transplantation reduced the autophagy presented as decreased levels of LC3 I/II, Beclin-1, and Atg5 (P < 0.01 and P < 0.05 and P < 0.05), and increased levels of p62 protein (P < 0.05), which were similar to the tendency in the SP600125 group. With the anisomycin treatment, the expression levels of LC3 I/II and Atg5 were increased (P < 0.001 and P < 0.05), while the expression levels of p62 protein were decreased (P < 0.01) (Fig. 6).Additionally, comparing with the NC group, the fluorescence intensity of GCs stained with MDC was obviously increased (P < 0.001), while it was decreased in the shHO-1 group (P < 0.05, Fig. 7), which represents that HO-1 expressed in MSCs can enhance the autophagy ability of GCs in the therapeutic process. And with the anisomycin administration, the intensity of MDC was improved (P < 0.001), while the SP600125 treatment inhibited the intensity (P < 0.01). To further confirm the researches above, the structure changes of autophagosome in GCs were observed by TEM, which showed the accumulated number of lamellar structures and cytosolic autophagic vacuoles in the HO-1-MSC group or anisomycin group as the morphology in the control group (white arrows). On the contrary, shHO-1-MSCs or SP600125-treated cells were morphologically distinct with breakup of the cell into numerous bodies and with chromatin condensation (black arrows) (Fig. 7). Based on the results above, we can suggest that HO-1 expressed in UCMSCs help recover the ovarian function in POFmice through activating the JNK/Bcl-2 signal pathway-regulated autophagy.
Fig. 7
Induction of autophagy in GCs in response to HO-1/shHO-1-MSCs, treated with or without anisomycin or SP600125. A-1–A-9 HN2-treated GCs co-cultured with UCMSCs transfected with HO-1/shHO-1 plasmids with or without the administration of SP600125 or anisomycin for 48 h in vitro. Representative fluorescent and phase-contrast images of the treated cells were shown. A-1 GC group. A-2 HN2 group. A-3 MSC group. A-4 NC group. A-5 HO-1 group. A-6 shHO-1 group. A-7 DMSO group. A-8 SP600125 group. A-9 Anisomycin group. A-10 Fluorescence intensity analysis of GCs in each group. B1–B9 POF mice transplanted with HO-1/shHO-1-MSCs and administrated with SP600125 or anisomycin for 48 h and imaged by TEM in vivo. Representative images of cells are shown as B1 control group. B2 POF group. B3 MSC group. B4 NC group. B5 HO-1 group. B6 shHO-1 group. B7 DMSO group. B8 Anisomycin group. B9 SP600125 group. White arrows indicate accumulation of autophagosome; black arrows indicate chromatin condensation. × 1900 (a), bar scale = 5 μm. × 4800 (b), bar scale = 2 μm. *P < 0.05, **P < 0.01, ***P < 0.001 vs POF, NC group, or DMSO group, separately. DMSO, dimethylsulfoxide; GCs, granulosa cells; HN2, chlormethine; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
Induction of autophagy in GCs in response to HO-1/shHO-1-MSCs, treated with or without anisomycin or SP600125. A-1–A-9 HN2-treated GCs co-cultured with UCMSCs transfected with HO-1/shHO-1 plasmids with or without the administration of SP600125 or anisomycin for 48 h in vitro. Representative fluorescent and phase-contrast images of the treated cells were shown. A-1 GC group. A-2 HN2 group. A-3 MSC group. A-4 NC group. A-5 HO-1 group. A-6 shHO-1 group. A-7 DMSO group. A-8 SP600125 group. A-9 Anisomycin group. A-10 Fluorescence intensity analysis of GCs in each group. B1–B9 POFmice transplanted with HO-1/shHO-1-MSCs and administrated with SP600125 or anisomycin for 48 h and imaged by TEM in vivo. Representative images of cells are shown as B1 control group. B2 POF group. B3 MSC group. B4 NC group. B5 HO-1 group. B6 shHO-1 group. B7 DMSO group. B8 Anisomycin group. B9 SP600125 group. White arrows indicate accumulation of autophagosome; black arrows indicate chromatin condensation. × 1900 (a), bar scale = 5 μm. × 4800 (b), bar scale = 2 μm. *P < 0.05, **P < 0.01, ***P < 0.001 vs POF, NC group, or DMSO group, separately. DMSO, dimethylsulfoxide; GCs, granulosa cells; HN2, chlormethine; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
HO-1-transfected UCMSC transplantation upregulates the ratios of CD8+CD28− T cells in POF mice
To assess the essential role of the CD8+CD28− T cells in the therapeutic process of POFmice receiving HO-1-MSC transplantation in vivo, spleen cells were separated and analyzed in each group (Fig. 8a). Comparing with the NC group, the frequency of CD8+CD28− T cells was higher in the HO-1 group (P < 0.01) but lower in the shHO-1 group (P < 0.05), which means HO-1 gene can help promote the therapeutic efficiency of MSCs through upregulating the expression levels of CD8+CD28− T cells (Fig. 8d). Moreover, much higher frequency of the cells was exhibited in mice with the administration of anisomycin (P < 0.05), and lower frequency was presented with SP600125 treatment (P < 0.001, Fig. 8c). Because IL-10 is one of the key predictors of inflammation produced by CD8+CD28− T cells [36], it can be further detected to confirm the expression of CD8+CD28− T cells during the therapeutic process. As showed in Fig. 3, with HO-1 transfection, the expression levels of IL-10 in mouse serum were elevated, showed as the similar tendency with the anisomycin group (P < 0.01, respectively); however, the expression were obviously reduced in mice with shHO-1-transfected MSC transplantation (P < 0.01) or with the administration of SP600125 (P < 0.01). Taken together, we can conclude that HO-1 helps improve the therapeutic role of MSCs through increase in the circulating of CD8+CD28− T Cells.
Fig. 8
Effects of HO-1 gene expressed in the UCMSCs on ratios of CD8+CD28− T cells with the administration of anisomycin or SP600125. a Representative flow cytometric plots for CD8+CD28− T acquisition isolated from spleens in the nine groups, respectively. b The CD8+CD28− T cells population comparison among the control group, POF group, and MSC group. c The CD8+CD28− T cells population comparison among the DMSO group, SP600125 group, and anisomycin group. d The CD8+CD28− T cells population comparison among the NC group, HO-1 group, and shHO-1 group. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
Effects of HO-1 gene expressed in the UCMSCs on ratios of CD8+CD28− T cells with the administration of anisomycin or SP600125. a Representative flow cytometric plots for CD8+CD28− T acquisition isolated from spleens in the nine groups, respectively. b The CD8+CD28− T cells population comparison among the control group, POF group, and MSC group. c The CD8+CD28− T cells population comparison among the DMSO group, SP600125 group, and anisomycin group. d The CD8+CD28− T cells population comparison among the NC group, HO-1 group, and shHO-1 group. *P < 0.05, **P < 0.01, ***P < 0.001 vs DMSO, GC group, or NC group, separately. DMSO, dimethylsulfoxide; HO-1, heme oxygenase-1; NC, empty vector; POF, premature ovarian failure; UCMSCs, umbilical cord mesenchymal stem cells
Discussion
Evidences have demonstrated that downregulated HO-1 levels were showed in abnormal metabolic states, and upregulated levels of HO-1 might suppress the inflammatory response and ameliorate metabolic disorders [34, 36]. However, it is still unknown if HO-1 expressed in UCMSCs is essential in recovering the ovarian function of POFmice receiving MSC transplantation. By comparing the outcomes of HO-1/shHO-1-transfected-UCMSC transplantation, we have confirmed that the ovarian function recovery is associated to the presence/absence of HO-1. Absence of HO-1 in UCMSC transplantation inhibits the GCs’ viability and activates their apoptosis in vitro. It also shows the decreased levels of E2 and AMH, the increased levels of FSH and LH in mice serum, the enhanced ovarian fibrosis, and the decreased functional follicles in vivo. However, the presence of HO-1 in UCMSC transplantation significantly recovers the ovarian function of POFmice with all these indices improved. Based upon these evidences, we can primary recognize that HO-1 expressed in UCMSCs played a critical therapeutic role in recovering the ovarian function of POFmice with UCMSC transplantation.JNK can activate the autophagy through disruption of the Bcl-2/Beclin1 complex [29]. To reveal whether the JNK/Bcl-2 signaling pathway is involved in such recovery, we also used SP600125/anisomycin-treated mice to compare multiple ovarian functional indices. Similar outcomes are observed between mice with shHO-1-UCMSC transplantation and with SP600125 administration, as well as between mice with HO-1-UCMSC transplantation and with anisomycin administration. Results showed that both the administration of SP600125 and the transplantation of shHO-1-UCMSC inhibit the p-JNk expression, and the therapeutic efficiency was downregulated, which presented as decreased GCs’ viability and increased apoptosis in vitro, along with abnormal serum levels such as increased serum levels of FSH and LH, decreased levels of E2 and AMH, and the observation of ovarian fibrosis, declined number of functional follicles and inclined number of atretic follicles in vivo. HO-1-UCMSCs and anisomycin activate the JNK/Bcl-2 signaling pathway, and the changes above can be reversed.As a cell degradation process, autophagy devours injured organelles and dysfunctional cytoplasm to maintain cell function [37], which is active in cells in physiological state, and can also be induced in response to cellular stress [38]. To figure out the critical role of the autophagy in the therapeutic process and its association with the JNK/Bcl-2 signal pathway and HO-1 gene, the expression levels of autophagy markers like LC3-II/I, Beclin1, p62, and Atg5 were measured in different conditions. LC3 conversion (LC3-I to LC3-II) reflects the progression of autophagy [39]; SQSTM1/p62 is widely used as a marker for autophagic flux [39-41], which is efficiently degraded by autophagy [42]. Atg5 is associated with phagophore formation [43], and beclin1 can direct the initiation phase and maturation-fusion phase [44]. Results showed that in mice with shHO-1-MSC transplantation or with the administration of SP600125, restrained autophagy in GCs were detected, including decreased expression levels of LC3-II, beclin1, and Atg5 but increased p62. Meanwhile, in mice transplanted with HO-1-MSCs or treated with anisomycin, the autophagy in GCs can be obviously activated, shown as increased levels of LC3-II, beclin1, and Atg5 but decreased p62. It is known that increased levels of autophagosomes can enhance its own formation and/or block the lysosomal processing [45]. In this study, decreased number of autophagosomes and receded intensity of fluorescence by MDC were observed in mice transplanted with shHO-1-MSCs or treated with SP600125, also with the observation of nucleolus shrinked and chromatin condensation. However, HO-1-MSC transplantation or anisomycin treatment can significantly increase the number of autophagosomes and numerous lamellar structures with cytosolic autophagic vacuoles with a relatively intact nucleus, and enhanced intensity of fluorescence by MDC. The positive and the negative results suggest the critical role of HO-1 in ovarian function by activating the JNK/Bcl-2 signaling pathway to regulate the autophagy.Researches showed that the CD8+CD28− T cells showed similar pleiotropic immunologic suppression to the traditional regulatory T cells [46]. In our study, the circulating CD8+CD28− T cells inclined in mice with HO-1-MSC transplantation compared with that in the NC group, but declined in mice with shHO-1-MSC transplantation, suggesting that HO-1 played a critical role in the therapeutic process and a high level of CD8+CD28− T cells is favorable for improving the therapeutic efficiency. IL-10 is one of the key predictors of inflammation produced by CD8+CD28− T cells, which work on regulating T cell responses [47]. The upregulation level of IL-10 in the HO-1 group and downregulation level in the shHO-1 group further indicates that HO-1 played its role through upregulating the expression of CD8+CD28− T cells.
Conclusions
In summary, we have shown that HO-1 gene expressed in UCMSCs can help recover the ovarian function of POFmice with UCMSC transplantation through activating the JNK/Bcl-2 signal pathway-regulated autophagy and upregulating the circulating of CD8+CD28− T cells. These findings provide a new target for the subsequent MSC-based therapies in humans in clinical.
Authors: Thomas R Gawriluk; Amber N Hale; Jodi A Flaws; Christopher P Dillon; Douglas R Green; Edmund B Rucker Journal: Reproduction Date: 2011-04-04 Impact factor: 3.906
Authors: Daniel J Klionsky; Fabio C Abdalla; Hagai Abeliovich; Robert T Abraham; Abraham Acevedo-Arozena; Khosrow Adeli; Lotta Agholme; Maria Agnello; Patrizia Agostinis; Julio A Aguirre-Ghiso; Hyung Jun Ahn; Ouardia Ait-Mohamed; Slimane Ait-Si-Ali; Takahiko Akematsu; Shizuo Akira; Hesham M Al-Younes; Munir A Al-Zeer; Matthew L Albert; Roger L Albin; Javier Alegre-Abarrategui; Maria Francesca Aleo; Mehrdad Alirezaei; Alexandru Almasan; Maylin Almonte-Becerril; Atsuo Amano; Ravi Amaravadi; Shoba Amarnath; Amal O Amer; Nathalie Andrieu-Abadie; Vellareddy Anantharam; David K Ann; Shailendra Anoopkumar-Dukie; Hiroshi Aoki; Nadezda Apostolova; Giuseppe Arancia; John P Aris; Katsuhiko Asanuma; Nana Y O Asare; Hisashi Ashida; Valerie Askanas; David S Askew; Patrick Auberger; Misuzu Baba; Steven K Backues; Eric H Baehrecke; Ben A Bahr; Xue-Yuan Bai; Yannick Bailly; Robert Baiocchi; Giulia Baldini; Walter Balduini; Andrea Ballabio; Bruce A Bamber; Edward T W Bampton; Gábor Bánhegyi; Clinton R Bartholomew; Diane C Bassham; Robert C Bast; Henri Batoko; Boon-Huat Bay; Isabelle Beau; Daniel M Béchet; Thomas J Begley; Christian Behl; Christian Behrends; Soumeya Bekri; Bryan Bellaire; Linda J Bendall; Luca Benetti; Laura Berliocchi; Henri Bernardi; Francesca Bernassola; Sébastien Besteiro; Ingrid Bhatia-Kissova; Xiaoning Bi; Martine Biard-Piechaczyk; Janice S Blum; Lawrence H Boise; Paolo Bonaldo; David L Boone; Beat C Bornhauser; Karina R Bortoluci; Ioannis Bossis; Frédéric Bost; Jean-Pierre Bourquin; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan R Brady; Claudio Brancolini; Andreas Brech; Jay E Brenman; Ana Brennand; Emery H Bresnick; Patrick Brest; Dave Bridges; Molly L Bristol; Paul S Brookes; Eric J Brown; John H Brumell; Nicola Brunetti-Pierri; Ulf T Brunk; Dennis E Bulman; Scott J Bultman; Geert Bultynck; Lena F Burbulla; Wilfried Bursch; Jonathan P Butchar; Wanda Buzgariu; Sergio P Bydlowski; Ken Cadwell; Monika Cahová; Dongsheng Cai; Jiyang Cai; Qian Cai; Bruno Calabretta; Javier Calvo-Garrido; Nadine Camougrand; Michelangelo Campanella; Jenny Campos-Salinas; Eleonora Candi; Lizhi Cao; Allan B Caplan; Simon R Carding; Sandra M Cardoso; Jennifer S Carew; Cathleen R Carlin; Virginie Carmignac; Leticia A M Carneiro; Serena Carra; Rosario A Caruso; Giorgio Casari; Caty Casas; Roberta Castino; Eduardo Cebollero; Francesco Cecconi; Jean Celli; Hassan Chaachouay; Han-Jung Chae; Chee-Yin Chai; David C Chan; Edmond Y Chan; Raymond Chuen-Chung Chang; Chi-Ming Che; Ching-Chow Chen; Guang-Chao Chen; Guo-Qiang Chen; Min Chen; Quan Chen; Steve S-L Chen; WenLi Chen; Xi Chen; Xiangmei Chen; Xiequn Chen; Ye-Guang Chen; Yingyu Chen; Yongqiang Chen; Yu-Jen Chen; Zhixiang Chen; Alan Cheng; Christopher H K Cheng; Yan Cheng; Heesun Cheong; Jae-Ho Cheong; Sara Cherry; Russ Chess-Williams; Zelda H Cheung; Eric Chevet; Hui-Ling Chiang; Roberto Chiarelli; Tomoki Chiba; Lih-Shen Chin; Shih-Hwa Chiou; Francis V Chisari; Chi Hin Cho; Dong-Hyung Cho; Augustine M K Choi; DooSeok Choi; Kyeong Sook Choi; Mary E Choi; Salem Chouaib; Divaker Choubey; Vinay Choubey; Charleen T Chu; Tsung-Hsien Chuang; Sheau-Huei Chueh; Taehoon Chun; Yong-Joon Chwae; Mee-Len Chye; Roberto Ciarcia; Maria R Ciriolo; Michael J Clague; Robert S B Clark; Peter G H Clarke; Robert Clarke; Patrice Codogno; Hilary A Coller; María I Colombo; Sergio Comincini; Maria Condello; Fabrizio Condorelli; Mark R Cookson; Graham H Coombs; Isabelle Coppens; Ramon Corbalan; Pascale Cossart; Paola Costelli; Safia Costes; Ana Coto-Montes; Eduardo Couve; Fraser P Coxon; James M Cregg; José L Crespo; Marianne J Cronjé; Ana Maria Cuervo; Joseph J Cullen; Mark J Czaja; Marcello D'Amelio; Arlette Darfeuille-Michaud; Lester M Davids; Faith E Davies; Massimo De Felici; John F de Groot; Cornelis A M de Haan; Luisa De Martino; Angelo De Milito; Vincenzo De Tata; Jayanta Debnath; Alexei Degterev; Benjamin Dehay; Lea M D Delbridge; Francesca Demarchi; Yi Zhen Deng; Jörn Dengjel; Paul Dent; Donna Denton; Vojo Deretic; Shyamal D Desai; Rodney J Devenish; Mario Di Gioacchino; Gilbert Di Paolo; Chiara Di Pietro; Guillermo Díaz-Araya; Inés Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Ivan Dikic; Savithramma P Dinesh-Kumar; Wen-Xing Ding; Clark W Distelhorst; Abhinav Diwan; Mojgan Djavaheri-Mergny; Svetlana Dokudovskaya; Zheng Dong; Frank C Dorsey; Victor Dosenko; James J Dowling; Stephen Doxsey; Marlène Dreux; Mark E Drew; Qiuhong Duan; Michel A Duchosal; Karen Duff; Isabelle Dugail; Madeleine Durbeej; Michael Duszenko; Charles L Edelstein; Aimee L Edinger; Gustavo Egea; Ludwig Eichinger; N Tony Eissa; Suhendan Ekmekcioglu; Wafik S El-Deiry; Zvulun Elazar; Mohamed Elgendy; Lisa M Ellerby; Kai Er Eng; Anna-Mart Engelbrecht; Simone Engelender; Jekaterina Erenpreisa; Ricardo Escalante; Audrey Esclatine; Eeva-Liisa Eskelinen; Lucile Espert; Virginia Espina; Huizhou Fan; Jia Fan; Qi-Wen Fan; Zhen Fan; Shengyun Fang; Yongqi Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Jean-Claude Farré; Mathias Faure; Marcus Fechheimer; Carl G Feng; Jian Feng; Qili Feng; Youji Feng; László Fésüs; Ralph Feuer; Maria E Figueiredo-Pereira; Gian Maria Fimia; Diane C Fingar; Steven Finkbeiner; Toren Finkel; Kim D Finley; Filomena Fiorito; Edward A Fisher; Paul B Fisher; Marc Flajolet; Maria L Florez-McClure; Salvatore Florio; Edward A Fon; Francesco Fornai; Franco Fortunato; Rati Fotedar; Daniel H Fowler; Howard S Fox; Rodrigo Franco; Lisa B Frankel; Marc Fransen; José M Fuentes; Juan Fueyo; Jun Fujii; Kozo Fujisaki; Eriko Fujita; Mitsunori Fukuda; Ruth H Furukawa; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Brigitte Galliot; Vincent Galy; Subramaniam Ganesh; Barry Ganetzky; Ian G Ganley; Fen-Biao Gao; George F Gao; Jinming Gao; Lorena Garcia; Guillermo Garcia-Manero; Mikel Garcia-Marcos; Marjan Garmyn; Andrei L Gartel; Evelina Gatti; Mathias Gautel; Thomas R Gawriluk; Matthew E Gegg; Jiefei Geng; Marc Germain; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Pradipta Ghosh; Anna M Giammarioli; Alexandra N Giatromanolaki; Spencer B Gibson; Robert W Gilkerson; Michael L Ginger; Henry N Ginsberg; Jakub Golab; Michael S Goligorsky; Pierre Golstein; Candelaria Gomez-Manzano; Ebru Goncu; Céline Gongora; Claudio D Gonzalez; Ramon Gonzalez; Cristina González-Estévez; Rosa Ana González-Polo; Elena Gonzalez-Rey; Nikolai V Gorbunov; Sharon Gorski; Sandro Goruppi; Roberta A Gottlieb; Devrim Gozuacik; Giovanna Elvira Granato; Gary D Grant; Kim N Green; Aleš Gregorc; Frédéric Gros; Charles Grose; Thomas W Grunt; Philippe Gual; Jun-Lin Guan; Kun-Liang Guan; Sylvie M Guichard; Anna S Gukovskaya; Ilya Gukovsky; Jan Gunst; Asa B Gustafsson; Andrew J Halayko; Amber N Hale; Sandra K Halonen; Maho Hamasaki; Feng Han; Ting Han; Michael K Hancock; Malene Hansen; Hisashi Harada; Masaru Harada; Stefan E Hardt; J Wade Harper; Adrian L Harris; James Harris; Steven D Harris; Makoto Hashimoto; Jeffrey A Haspel; Shin-ichiro Hayashi; Lori A Hazelhurst; Congcong He; You-Wen He; Marie-Joseé Hébert; Kim A Heidenreich; Miep H Helfrich; Gudmundur V Helgason; Elizabeth P Henske; Brian Herman; Paul K Herman; Claudio Hetz; Sabine Hilfiker; Joseph A Hill; Lynne J Hocking; Paul Hofman; Thomas G Hofmann; Jörg Höhfeld; Tessa L Holyoake; Ming-Huang Hong; David A Hood; Gökhan S Hotamisligil; Ewout J Houwerzijl; Maria Høyer-Hansen; Bingren Hu; Chien-An A Hu; Hong-Ming Hu; Ya Hua; Canhua Huang; Ju Huang; Shengbing Huang; Wei-Pang Huang; Tobias B Huber; Won-Ki Huh; Tai-Ho Hung; Ted R Hupp; Gang Min Hur; James B Hurley; Sabah N A Hussain; Patrick J Hussey; Jung Jin Hwang; Seungmin Hwang; Atsuhiro Ichihara; Shirin Ilkhanizadeh; Ken Inoki; Takeshi Into; Valentina Iovane; Juan L Iovanna; Nancy Y Ip; Yoshitaka Isaka; Hiroyuki Ishida; Ciro Isidoro; Ken-ichi Isobe; Akiko Iwasaki; Marta Izquierdo; Yotaro Izumi; Panu M Jaakkola; Marja Jäättelä; George R Jackson; William T Jackson; Bassam Janji; Marina Jendrach; Ju-Hong Jeon; Eui-Bae Jeung; Hong Jiang; Hongchi Jiang; Jean X Jiang; Ming Jiang; Qing Jiang; Xuejun Jiang; Xuejun Jiang; Alberto Jiménez; Meiyan Jin; Shengkan Jin; Cheol O Joe; Terje Johansen; Daniel E Johnson; Gail V W Johnson; Nicola L Jones; Bertrand Joseph; Suresh K Joseph; Annie M Joubert; Gábor Juhász; Lucienne Juillerat-Jeanneret; Chang Hwa Jung; Yong-Keun Jung; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Motoni Kadowaki; Katarina Kagedal; Yoshiaki Kamada; Vitaliy O Kaminskyy; Harm H Kampinga; Hiromitsu Kanamori; Chanhee Kang; Khong Bee Kang; Kwang Il Kang; Rui Kang; Yoon-A Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Arthi Kanthasamy; Vassiliki Karantza; Gur P Kaushal; Susmita Kaushik; Yoshinori Kawazoe; Po-Yuan Ke; John H Kehrl; Ameeta Kelekar; Claus Kerkhoff; David H Kessel; Hany Khalil; Jan A K W Kiel; Amy A Kiger; Akio Kihara; Deok Ryong Kim; Do-Hyung Kim; Dong-Hou Kim; Eun-Kyoung Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; John K Kim; Peter K Kim; Seong Who Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Jason S King; Timothy J Kinsella; Vladimir Kirkin; Lorrie A Kirshenbaum; Katsuhiko Kitamoto; Kaio Kitazato; Ludger Klein; Walter T Klimecki; Jochen Klucken; Erwin Knecht; Ben C B Ko; Jan C Koch; Hiroshi Koga; Jae-Young Koh; Young Ho Koh; Masato Koike; Masaaki Komatsu; Eiki Kominami; Hee Jeong Kong; Wei-Jia Kong; Viktor I Korolchuk; Yaichiro Kotake; Michael I Koukourakis; Juan B Kouri Flores; Attila L Kovács; Claudine Kraft; Dimitri Krainc; Helmut Krämer; Carole Kretz-Remy; Anna M Krichevsky; Guido Kroemer; Rejko Krüger; Oleg Krut; Nicholas T Ktistakis; Chia-Yi Kuan; Roza Kucharczyk; Ashok Kumar; Raj Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Tino Kurz; Ho Jeong Kwon; Albert R La Spada; Frank Lafont; Trond Lamark; Jacques Landry; Jon D Lane; Pierre Lapaquette; Jocelyn F Laporte; Lajos László; Sergio Lavandero; Josée N Lavoie; Robert Layfield; Pedro A Lazo; Weidong Le; Laurent Le Cam; Daniel J Ledbetter; Alvin J X Lee; Byung-Wan Lee; Gyun Min Lee; Jongdae Lee; Ju-Hyun Lee; Michael Lee; Myung-Shik Lee; Sug Hyung Lee; Christiaan Leeuwenburgh; Patrick Legembre; Renaud Legouis; Michael Lehmann; Huan-Yao Lei; Qun-Ying Lei; David A Leib; José Leiro; John J Lemasters; Antoinette Lemoine; Maciej S Lesniak; Dina Lev; Victor V Levenson; Beth Levine; Efrat Levy; Faqiang Li; Jun-Lin Li; Lian Li; Sheng Li; Weijie Li; Xue-Jun Li; Yan-bo Li; Yi-Ping Li; Chengyu Liang; Qiangrong Liang; Yung-Feng Liao; Pawel P Liberski; Andrew Lieberman; Hyunjung J Lim; Kah-Leong Lim; Kyu Lim; Chiou-Feng Lin; Fu-Cheng Lin; Jian Lin; Jiandie D Lin; Kui Lin; Wan-Wan Lin; Weei-Chin Lin; Yi-Ling Lin; Rafael Linden; Paul Lingor; Jennifer Lippincott-Schwartz; Michael P Lisanti; Paloma B Liton; Bo Liu; Chun-Feng Liu; Kaiyu Liu; Leyuan Liu; Qiong A Liu; Wei Liu; Young-Chau Liu; Yule Liu; Richard A Lockshin; Chun-Nam Lok; Sagar Lonial; Benjamin Loos; Gabriel Lopez-Berestein; Carlos López-Otín; Laura Lossi; Michael T Lotze; Peter Lőw; Binfeng Lu; Bingwei Lu; Bo Lu; Zhen Lu; Frédéric Luciano; Nicholas W Lukacs; Anders H Lund; Melinda A Lynch-Day; Yong Ma; Fernando Macian; Jeff P MacKeigan; Kay F Macleod; Frank Madeo; Luigi Maiuri; Maria Chiara Maiuri; Davide Malagoli; May Christine V Malicdan; Walter Malorni; Na Man; Eva-Maria Mandelkow; Stéphen Manon; Irena Manov; Kai Mao; Xiang Mao; Zixu Mao; Philippe Marambaud; Daniela Marazziti; Yves L Marcel; Katie Marchbank; Piero Marchetti; Stefan J Marciniak; Mateus Marcondes; Mohsen Mardi; Gabriella Marfe; Guillermo Mariño; Maria Markaki; Mark R Marten; Seamus J Martin; Camille Martinand-Mari; Wim Martinet; Marta Martinez-Vicente; Matilde Masini; Paola Matarrese; Saburo Matsuo; Raffaele Matteoni; Andreas Mayer; Nathalie M Mazure; David J McConkey; Melanie J McConnell; Catherine McDermott; Christine McDonald; Gerald M McInerney; Sharon L McKenna; BethAnn McLaughlin; Pamela J McLean; Christopher R McMaster; G Angus McQuibban; Alfred J Meijer; Miriam H Meisler; Alicia Meléndez; Thomas J Melia; Gerry Melino; Maria A Mena; Javier A Menendez; Rubem F S Menna-Barreto; Manoj B Menon; Fiona M Menzies; Carol A Mercer; Adalberto Merighi; Diane E Merry; Stefania Meschini; Christian G Meyer; Thomas F Meyer; Chao-Yu Miao; Jun-Ying Miao; Paul A M Michels; Carine Michiels; Dalibor Mijaljica; Ana Milojkovic; Saverio Minucci; Clelia Miracco; Cindy K Miranti; Ioannis Mitroulis; Keisuke Miyazawa; Noboru Mizushima; Baharia Mograbi; Simin Mohseni; Xavier Molero; Bertrand Mollereau; Faustino Mollinedo; Takashi Momoi; Iryna Monastyrska; Martha M Monick; Mervyn J Monteiro; Michael N Moore; Rodrigo Mora; Kevin Moreau; Paula I Moreira; Yuji Moriyasu; Jorge Moscat; Serge Mostowy; Jeremy C Mottram; Tomasz Motyl; Charbel E-H Moussa; Sylke Müller; Sylviane Muller; Karl Münger; Christian Münz; Leon O Murphy; Maureen E Murphy; Antonio Musarò; Indira Mysorekar; Eiichiro Nagata; Kazuhiro Nagata; Aimable Nahimana; Usha Nair; Toshiyuki Nakagawa; Kiichi Nakahira; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Naweed I Naqvi; Derek P Narendra; Masashi Narita; Miguel Navarro; Steffan T Nawrocki; Taras Y Nazarko; Andriy Nemchenko; Mihai G Netea; Thomas P Neufeld; Paul A Ney; Ioannis P Nezis; Huu Phuc Nguyen; Daotai Nie; Ichizo Nishino; Corey Nislow; Ralph A Nixon; Takeshi Noda; Angelika A Noegel; Anna Nogalska; Satoru Noguchi; Lucia Notterpek; Ivana Novak; Tomoyoshi Nozaki; Nobuyuki Nukina; Thorsten Nürnberger; Beat Nyfeler; Keisuke Obara; Terry D Oberley; Salvatore Oddo; Michinaga Ogawa; Toya Ohashi; Koji Okamoto; Nancy L Oleinick; F Javier Oliver; Laura J Olsen; Stefan Olsson; Onya Opota; Timothy F Osborne; Gary K Ostrander; Kinya Otsu; Jing-hsiung James Ou; Mireille Ouimet; Michael Overholtzer; Bulent Ozpolat; Paolo Paganetti; Ugo Pagnini; Nicolas Pallet; Glen E Palmer; Camilla Palumbo; Tianhong Pan; Theocharis Panaretakis; Udai Bhan Pandey; Zuzana Papackova; Issidora Papassideri; Irmgard Paris; Junsoo Park; Ohkmae K Park; Jan B Parys; Katherine R Parzych; Susann Patschan; Cam Patterson; Sophie Pattingre; John M Pawelek; Jianxin Peng; David H Perlmutter; Ida Perrotta; George Perry; Shazib Pervaiz; Matthias Peter; Godefridus J Peters; Morten Petersen; Goran Petrovski; James M Phang; Mauro Piacentini; Philippe Pierre; Valérie Pierrefite-Carle; Gérard Pierron; Ronit Pinkas-Kramarski; Antonio Piras; Natik Piri; Leonidas C Platanias; Stefanie Pöggeler; Marc Poirot; Angelo Poletti; Christian Poüs; Mercedes Pozuelo-Rubio; Mette Prætorius-Ibba; Anil Prasad; Mark Prescott; Muriel Priault; Nathalie Produit-Zengaffinen; Ann Progulske-Fox; Tassula Proikas-Cezanne; Serge Przedborski; Karin Przyklenk; Rosa Puertollano; Julien Puyal; Shu-Bing Qian; Liang Qin; Zheng-Hong Qin; Susan E Quaggin; Nina Raben; Hannah Rabinowich; Simon W Rabkin; Irfan Rahman; Abdelhaq Rami; Georg Ramm; Glenn Randall; Felix Randow; V Ashutosh Rao; Jeffrey C Rathmell; Brinda Ravikumar; Swapan K Ray; Bruce H Reed; John C Reed; Fulvio Reggiori; Anne Régnier-Vigouroux; Andreas S Reichert; John J Reiners; Russel J Reiter; Jun Ren; José L Revuelta; Christopher J Rhodes; Konstantinos Ritis; Elizete Rizzo; Jeffrey Robbins; Michel Roberge; Hernan Roca; Maria C Roccheri; Stephane Rocchi; H Peter Rodemann; Santiago Rodríguez de Córdoba; Bärbel Rohrer; Igor B Roninson; Kirill Rosen; Magdalena M Rost-Roszkowska; Mustapha Rouis; Kasper M A Rouschop; Francesca Rovetta; Brian P Rubin; David C Rubinsztein; Klaus Ruckdeschel; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Nelson Ruiz-Opazo; Rossella Russo; Tor Erik Rusten; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Junichi Sadoshima; Tapas Saha; Tatsuya Saitoh; Hiroshi Sakagami; Yasuyoshi Sakai; Ghasem Hoseini Salekdeh; Paolo Salomoni; Paul M Salvaterra; Guy Salvesen; Rosa Salvioli; Anthony M J Sanchez; José A Sánchez-Alcázar; Ricardo Sánchez-Prieto; Marco Sandri; Uma Sankar; Poonam Sansanwal; Laura Santambrogio; Shweta Saran; Sovan Sarkar; Minnie Sarwal; Chihiro Sasakawa; Ausra Sasnauskiene; Miklós Sass; Ken Sato; Miyuki Sato; Anthony H V Schapira; Michael Scharl; Hermann M Schätzl; Wiep Scheper; Stefano Schiaffino; Claudio Schneider; Marion E Schneider; Regine Schneider-Stock; Patricia V Schoenlein; Daniel F Schorderet; Christoph Schüller; Gary K Schwartz; Luca Scorrano; Linda Sealy; Per O Seglen; Juan Segura-Aguilar; Iban Seiliez; Oleksandr Seleverstov; Christian Sell; Jong Bok Seo; Duska Separovic; Vijayasaradhi Setaluri; Takao Setoguchi; Carmine Settembre; John J Shacka; Mala Shanmugam; Irving M Shapiro; Eitan Shaulian; Reuben J Shaw; James H Shelhamer; Han-Ming Shen; Wei-Chiang Shen; Zu-Hang Sheng; Yang Shi; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Takahiro Shintani; Orian S Shirihai; Gordon C Shore; Andriy A Sibirny; Stan B Sidhu; Beata Sikorska; Elaine C M Silva-Zacarin; Alison Simmons; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Anne Simonsen; David A Sinclair; Rajat Singh; Debasish Sinha; Frank A Sinicrope; Agnieszka Sirko; Parco M Siu; Efthimios Sivridis; Vojtech Skop; Vladimir P Skulachev; Ruth S Slack; Soraya S Smaili; Duncan R Smith; Maria S Soengas; Thierry Soldati; Xueqin Song; Anil K Sood; Tuck Wah Soong; Federica Sotgia; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Srinivasa M Srinivasula; Leonidas Stefanis; Joan S Steffan; Ruediger Stendel; Harald Stenmark; Anastasis Stephanou; Stephan T Stern; Cinthya Sternberg; Björn Stork; Peter Strålfors; Carlos S Subauste; Xinbing Sui; David Sulzer; Jiaren Sun; Shi-Yong Sun; Zhi-Jun Sun; Joseph J Y Sung; Kuninori Suzuki; Toshihiko Suzuki; Michele S Swanson; Charles Swanton; Sean T Sweeney; Lai-King Sy; Gyorgy Szabadkai; Ira Tabas; Heinrich Taegtmeyer; Marco Tafani; Krisztina Takács-Vellai; Yoshitaka Takano; Kaoru Takegawa; Genzou Takemura; Fumihiko Takeshita; Nicholas J Talbot; Kevin S W Tan; Keiji Tanaka; Kozo Tanaka; Daolin Tang; Dingzhong Tang; Isei Tanida; Bakhos A Tannous; Nektarios Tavernarakis; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Lance S Terada; Alexei Terman; Gianluca Tettamanti; Karin Thevissen; Craig B Thompson; Andrew Thorburn; Michael Thumm; FengFeng Tian; Yuan Tian; Glauco Tocchini-Valentini; Aviva M Tolkovsky; Yasuhiko Tomino; Lars Tönges; Sharon A Tooze; Cathy Tournier; John Tower; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Ting-Fen Tsai; Mario P Tschan; Takeshi Tsubata; Allan Tsung; Boris Turk; Lorianne S Turner; Suresh C Tyagi; Yasuo Uchiyama; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Vivek K Unni; Maria I Vaccaro; Enza Maria Valente; Greet Van den Berghe; Ida J van der Klei; Wouter van Doorn; Linda F van Dyk; Marjolein van Egmond; Leo A van Grunsven; Peter Vandenabeele; Wim P Vandenberghe; Ilse Vanhorebeek; Eva C Vaquero; Guillermo Velasco; Tibor Vellai; Jose Miguel Vicencio; Richard D Vierstra; Miquel Vila; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Olga V Voitsekhovskaja; Clarissa von Haefen; Marcela Votruba; Keiji Wada; Richard Wade-Martins; Cheryl L Walker; Craig M Walsh; Jochen Walter; Xiang-Bo Wan; Aimin Wang; Chenguang Wang; Dawei Wang; Fan Wang; Fen Wang; Guanghui Wang; Haichao Wang; Hong-Gang Wang; Horng-Dar Wang; Jin Wang; Ke Wang; Mei Wang; Richard C Wang; Xinglong Wang; Xuejun Wang; Ying-Jan Wang; Yipeng Wang; Zhen Wang; Zhigang Charles Wang; Zhinong Wang; Derick G Wansink; Diane M Ward; Hirotaka Watada; Sarah L Waters; Paul Webster; Lixin Wei; Conrad C Weihl; William A Weiss; Scott M Welford; Long-Ping Wen; Caroline A Whitehouse; J Lindsay Whitton; Alexander J Whitworth; Tom Wileman; John W Wiley; Simon Wilkinson; Dieter Willbold; Roger L Williams; Peter R Williamson; Bradly G Wouters; Chenghan Wu; Dao-Cheng Wu; William K K Wu; Andreas Wyttenbach; Ramnik J Xavier; Zhijun Xi; Pu Xia; Gengfu Xiao; Zhiping Xie; Zhonglin Xie; Da-zhi Xu; Jianzhen Xu; Liang Xu; Xiaolei Xu; Ai Yamamoto; Akitsugu Yamamoto; Shunhei Yamashina; Michiaki Yamashita; Xianghua Yan; Mitsuhiro Yanagida; Dun-Sheng Yang; Elizabeth Yang; Jin-Ming Yang; Shi Yu Yang; Wannian Yang; Wei Yuan Yang; Zhifen Yang; Meng-Chao Yao; Tso-Pang Yao; Behzad Yeganeh; Wei-Lien Yen; Jia-jing Yin; Xiao-Ming Yin; Ook-Joon Yoo; Gyesoon Yoon; Seung-Yong Yoon; Tomohiro Yorimitsu; Yuko Yoshikawa; Tamotsu Yoshimori; Kohki Yoshimoto; Ho Jin You; Richard J Youle; Anas Younes; Li Yu; Long Yu; Seong-Woon Yu; Wai Haung Yu; Zhi-Min Yuan; Zhenyu Yue; Cheol-Heui Yun; Michisuke Yuzaki; Olga Zabirnyk; Elaine Silva-Zacarin; David Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Zahra Zakeri; Herbert J Zeh; Scott O Zeitlin; Hong Zhang; Hui-Ling Zhang; Jianhua Zhang; Jing-Pu Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xu Dong Zhang; Mantong Zhao; Yi-Fang Zhao; Ying Zhao; Zhizhuang J Zhao; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Cong-Zhao Zhou; Changlian Zhu; Wei-Guo Zhu; Xiao-Feng Zhu; Xiongwei Zhu; Yuangang Zhu; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Jürgen Zschocke; Brian Zuckerbraun Journal: Autophagy Date: 2012-04 Impact factor: 16.016
Authors: Anna Lange-Consiglio; Emanuele Capra; Valentina Herrera; Ingrid Lang-Olip; Peter Ponsaerts; Fausto Cremonesi Journal: Front Bioeng Biotechnol Date: 2022-01-24
Authors: Alba María Polonio; Lucía Chico-Sordo; Isabel Córdova-Oriz; Marta Medrano; Juan A García-Velasco; Elisa Varela Journal: Yale J Biol Med Date: 2020-09-30